NDRA — ENDRA Life Sciences Share Price
Last trade - 00:00- $3.45m
- $0.23m
- 13
- 25
- 31
- 11
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.35 | ||
| Price to Tang. Book | 1.35 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -281.18% | ||
| Return on Equity | -280.02% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 0.1 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
Directors
- Francois Michelon CHM (55)
- Irina Pestrikova CFO (35)
- Michael Thornton CTO (52)
- Renaud Maloberti OTH (52)
- Louis Basenese IND (43)
- Anthony DiGiandomenico IND (54)
- Sanjiv Gambhir IND (57)
- Michael Harsh IND (66)
- Alexander Tokman IND (59)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 18th, 2007
- Public Since
- June 28th, 2017
- No. of Shareholders
- 24
- No. of Employees
- 21
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 562,213
- Address
- 3600 Green Ct Ste 350, ANN ARBOR, 48105-2440
- Web
- https://www.endrainc.com/
- Phone
- +1 7343350468
- Contact
- Yvonne Briggs
- Auditors
- RBSM LLP
Latest News for NDRA
Upcoming Events for NDRA
Q1 2025 ENDRA Life Sciences Inc Earnings Release
ENDRA Life Sciences Inc Annual Shareholders Meeting
Q2 2025 ENDRA Life Sciences Inc Earnings Release
Similar to NDRA
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 20:27 UTC, shares in ENDRA Life Sciences are trading at $6.15. This share price information is delayed by 15 minutes.
Shares in ENDRA Life Sciences last closed at $6.15 and the price had moved by -98.94% over the past 365 days. In terms of relative price strength the ENDRA Life Sciences share price has underperformed the S&P500 Index by -99.05% over the past year.
The overall consensus recommendation for ENDRA Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreENDRA Life Sciences does not currently pay a dividend.
ENDRA Life Sciences does not currently pay a dividend.
ENDRA Life Sciences does not currently pay a dividend.
To buy shares in ENDRA Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.15, shares in ENDRA Life Sciences had a market capitalisation of $3.45m.
Here are the trading details for ENDRA Life Sciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NDRA
Based on an overall assessment of its quality, value and momentum ENDRA Life Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in ENDRA Life Sciences is $75.00. That is 1120.5% above the last closing price of $6.15.
Analysts covering ENDRA Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$15.38 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ENDRA Life Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -36.78%.
As of the last closing price of $6.15, shares in ENDRA Life Sciences were trading -69.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ENDRA Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ENDRA Life Sciences' management team is headed by:
- Francois Michelon - CHM
- Irina Pestrikova - CFO
- Michael Thornton - CTO
- Renaud Maloberti - OTH
- Louis Basenese - IND
- Anthony DiGiandomenico - IND
- Sanjiv Gambhir - IND
- Michael Harsh - IND
- Alexander Tokman - IND